Tuesday, March 03, 2015

The Roots of Anxiety Induced Pain

Corticotropin-Releasing Factor and ERK1/2 Pathway

This study crossed my radar scope because the investigators referenced use of our phosphoERK1/2 for Western Blotting and Immunohistochemistry: Gisela Patrícia da Silva Borges , Juan Antonio Micó Segura , Fani Lourença Moreira Neto , Esther Berrocoso. Corticotropin-Releasing Factor Mediates Pain-Induced Anxiety through the ERK1/2 Signaling Cascade in Locus Coeruleus Neurons. DOI: First published online: 25 February 2015

Conclusion: pain-induced anxiety is mediated by CRF neurotransmission in the LC through ERK1/2 signaling cascade.

Figure: a) Schematic representation of the anatomical pathways implicated. Briefly, the contralateral LC indirectly receives inputs from the inflamed paw (red dashed line; ascending pathways) and, subsequently, the information is sent to corticolimbic areas. Additionally, the LC sends direct projections to the spinal cord (blue straight line; descending pathways). b) Body weight of the control and MA rats. c) Body rectal temperature of control and MA rats. d) Mechanical hyperalgesia represented by a significant decrease in the paw withdrawal threshold of the ipsilateral paw of MA rats. e) Mechanical allodynia represented by a significant decrease in the force threshold of the ipsilateral paw of MA rats. Graph depicting the expression of pERK1/2 in the LC after intra-LC administration of the αCRF receptor antagonist, showing that the significant increase of pERK1/2 in MA4W animals was no longer observed when this antagonist was administered.  g) Graph showing that the local administration of the αCRF antagonist had no significant effect on mechanical hyperalgesia in MA4W rats. h) Graph showing that local administration of h) Graph showing that local administration of the α-helical CRF antagonist had no significant effect on mechanical allodynia in the ipsilateral paw of MA rats. i) Graph showing that the time spent in the open arms decreased in MA4W rats receiving the vehicle alone but this effect was successfully reversed by administration of the αCRF antagonist. j) Graph showing that local administration of the α-helical CRF antagonist had no significant effect on the total distance traveled in the elevated zero maze. k) Graph showing that local administration of the α-helical CRF antagonist reversed the decrease in the number of entries into the open arms observed in MA4W rats receiving the vehicle alone. B=Baseline; LC=Locus Coeruleus; αCRF=antagonist of the corticotropin-releasing factor receptor I and II; W=Week; MA=Monoarthritis.

Western Blotting: The membranes were blocked with 5% Bovine Serum Albumin (BSA; Sigma, Spain) in TBST and probed overnight at 4 ºC with a rabbit anti-phospho-ERK1/2 (1:5,000; Neuromics). Immunohistochemistry: Brains were removed and processed for free-floating immunohistochemistry. One in five sequential transverse brain sections (30 µm) containing the PVN from each rat were washed, blocked and incubated with a rabbit antiserum against the phosphorylated ERK1 and ERK2 isoforms (pERK1/2; 1:1000; 48 hours at 4-8ºC: Neuromics, USA). Immunodetection was achieved with a biotinylated donkey anti-rabbit antiserum (1:500; 1 hour; Jackson ImmunoResearch, USA), followed by an ABC solution (1:200, 1 hour; ABC Elite kit, Vector Laboratories, UK) and a colorimetric reaction with 3,3-diaminobenzidine tetrahydrochloride (DAB; 10 min) in 0.05M Tris-HCl buffer containing 0.003% hydrogen peroxide (Cruz et al., 2005). Sections were then washed in PBS, mounted on gelatin-coated glass slides, cleared in xylene, cover-slipped with DPX and analyzed by light microscopy.

We have a broad range of pain and inflammatory response research markers. Check us out today.

Friday, February 27, 2015

Neurite Outgrowth Assays-96 Well Plates

Fast, Effective and Data Rich!

Our Customers' are reporting great results using our hN2 Primary Human Neurons. We are seeing a natural evolution for high content to high throughput screening. This is because our human neuron culturing kits are proving pure and potent (sample pubs).

Here's some customer data using hN2™ Human Neurons High Throughput Screening (HTS) Kit:

Image: Neurite Outgrowth Assay in 96 Well Plate using hN2 Neurons-Blue – Nuclear staining; Green – Neurite and cell body staining.

Want to learn more? Contact me directly at or 612-801-1007. Thank you. Pete Shuster, CEO and Owner, Neuromics.

Wednesday, February 25, 2015

Neuromics-ArunA Biomedical Partnership

We are Closer than Ever!

I spent the past several days meeting with Ms. Tracey Stice (COO), Dr. Steven Stice (President and CSO) and Ms. Joy Clark (Sales and Marketing Manager) at ArunA HQ in Athens, GA. The objective of the meeting was to finalize plans for our Strategic Selling Partnership. This partnership enables us to open up more cell based assay solutions to current and future Customers involved in neuro-diseases/disorders research and drug discovery.
The Aruna Team

...And the news gets better. By combining our expertise and experience, we are now well positioned to to:
  1. Shape new solutions and services that would more tightly aligned with your unique requirements
  2. Communicate how other labs within your organization are using our solutions and look for ways to leverage this.
  3. Track buying volume so we can give favorable pricing based on purchase made in total by your organization vs specific groups.
We will be working even harder to make sure you that you are satisfied with the value we bring to you and your team. Wondering what we can do for you today? You can contact me directly 612-801-1007 or Thank you. Pete Shuster, CEO, Neuromics AND ArunA Biomedical Strategic Selling Partner.

Saturday, February 21, 2015

i-Fect Delivers siRNA in vitro and in vivo

Gene Expression Analysis for Studying Stroke

We have posted over 35 publications that reference use of our i-Fect Transfection Kit to deliver siRNA, miRNA and shRNA in vitro and in vivo. Results documented in these publications prove that this kit is both non-toxic and delivers ultra-high transfection efficiency.

i-Fect Data Example

Figure. The effects of HDAC2 siRNA Infusion into the CeA of P rats on voluntary ethanol consumption as measured by the two-bottle free choice paradigm. Monitoring the voluntary ethanol consumption of alcohol-preferring (P) rats via the two bottle free choice paradigm following infusion of vehicle or histone deacetylase isoform 2 (HDAC2) siRNA into the central amygdala (CeA) demonstrates that high HDAC2 levels may mediate the high alcohol drinking behaviors of P rats. P rats were given access to water and 7% ethanol followed by water and 9% ethanol. On the sixth day of ethanol access P rats received infusion of vehicle or HDAC2 siRNA and consumption of water and 9% ethanol were monitored for sevnfusion. Total fluid intake did not significantly differ between the groups. Values are represented as the mean ± SEM of the ethanol consumption (g / kg / day) and total fluid intake (mL) plotted daily for n=6 rats per treatment group. *Significantly different between the groups.SACHIN MOONAT. The Role of Amygdaloid Chromatin and Synaptic Remodeling in Anxiety and Alcoholism. THESIS Submitted as partial fulfillment of the requirements for the degree of Doctor of Philosophy in Neuroscience in the Graduate College of the University of Illinois at Chicago, 2014.

Here's yet another recent publication highlighting use of i-Fect:

In this study data suggest the protective effects of EPO on NUV injuries are highly associated with the increase of p-Cx43, which improves GJIC to reduce neurotoxic substances: Ziyi Zhoua, Xiaobai Weib, Jun Xiang, Junpeng Gao, Lixin Wang, Jinsong You, Yefeng Cai , Dingfang Caid. Protection of erythropoietin against ischemic neurovascular unit injuries through the effects of connexin43. Biochemical and Biophysical Research Communications. doi:10.1016/j.bbrc.2015.02...The strands were incubated at 90°C for 5 min and then at 37°C for 1 h. SiRNA was prepared immediately before administration by mixing the RNA solution (1 μg/μl in annealing buffer) with the transfection reagent i-Fect (v/v: 1/3; Neuromics, Edina, MN, USA) to a final siRNA ...

•EPO has protective effects on ischemic NVU injuries.
•EPO up-regulates phosphorylation of Cx43, not total Cx43.
•EPO's protective effects on NUV injuries are p-Cx43-GJIC dependent.

Wednesday, February 11, 2015

Proven and Published Sandwich ELISA Kits

Growing Catalog of ELISA Kits

We are partnering with RayBiotech to manufacture our ELISA Kits. They have proven valuable additions to our Cell Based Assay solutions.

Neuromics has been built on a foundation of quality. RayBiotech's commitment to quality includes compliance to GLP/GMP FDA and ISO9000 regulations.
ELISA Kits Sample Data

Figure: Induction of proinflammatory cytokines is attenuated in CX3CL1−/− mice expressing sFKN. TNFα and IL-1β concentrations were measured using standard ELISA techniques for VM lysates. a, TNFα concentrations were upregulated following MPTP administration (three-way ANOVA; F(1, 23) = 18.36, ★★★p < 0.001). Comparatively, CX3CL1−/− mice expressing sFKN in the SNpc had significantly lower concentrations of TNFα relative to mFKN (Tukey's HSD; ***p < 0.001) and GFP (Tukey's HSD; ###p < 0.001) expressing mice. There were no significant differences between sFKN and WT-MPTP (Tukey's HSD; p = 0.384) or mFKN and GFP (Tukey's HSD; p = 0.773). b, The IL-1β concentrations in the VM were significantly upregulated for mice exposed to MPTP (three-way ANOVA; F(1, 23) = 11.97, ★★★p = 0.002). Similar to the pattern of TNFα, IL-1β concentrations in CX3CL1−/− mice expressing sFKN were significantly blunted compared to both mFKN (Tukey's HSD; ***p = 0.001) and GFP (Tukey's HSD; ###p < 0.001). As was observed with TNFα, there were no significant differences in IL-1β concentrations between WT-MPTP and sFKN (Tukey's HSD; p = 0.785) or mFKN and GFP (Tukey's HSD; p = 0.845) expressing mice. Data are presented as the mean ± SEM.

Questions? Please contact me directly, Pete Shuster, CEO and Owner, 612-801-1007 or Thank you.

Saturday, February 07, 2015

Your Feedback Matters

Our Solutions Must Work

We take our ability to serve you very seriously. We use bird-eye to make sure each and every one of our customers are pleased with results. If you are not happy, we do everything we can to fix your issue. This includes replacement and refunds:
Should you ever have questions or issues, I am at your "beck and call". Do not hesitate to contact me directly. Pete Shuster, CEO and Owner, Neuromics, 612-801-1007 or Thank you!

Saturday, January 31, 2015

Neural Progenitors and Cool Science

Titania Nanotubes and Neural Prostheses

I am always on the hunt for the use of our Neural Progenitor Markers in cool and important human health applications. Here our Nestin Antibody is use to access the growth and maintenance of C17.2 neural stem cell line cultured in these nanotubes: Jonathan A. Sorkin, Stephen Hughes, Paulo Soares, Ketul C. Popat. Titania nanotube arrays as interfaces for neural prostheses. Materials Science and Engineering: C Volume 49, 1 April 2015, Pages 735–745. doi:10.1016/j.msec.2015.01.077

Image: Nestin staining eSC Derived hNP1 Human Neural Progenitors. Cells were stained using goat anti-mouse Alexa Fluor 488 secondary antibody (green) (Molecular Probe, A-11001) and counterstained with DAPI (blue).

Abstract: Neural prostheses have become ever more acceptable treatments for many different types of neurological damage and disease. Here we investigate the use of two different morphologies of titania nanotube arrays as interfaces to advance the longevity and effectiveness of these prostheses. The nanotube arrays were characterized for their nanotopography, crystallinity, conductivity, wettability, surface mechanical properties and adsorption of key proteins: fibrinogen, albumin and laminin. The loosely packed nanotube arrays fabricated using a diethylene glycol based electrolyte, contained a higher presence of the anatase crystal phase and were subsequently more conductive. These arrays yielded surfaces with higher wettability and lower modulus than the densely packed nanotube arrays fabricated using water based electrolyte. Further the adhesion, proliferation and differentiation of the C17.2 neural stem cell line was investigated on the nanotube arrays. The proliferation ratio of the cells as well as the level of neuronal differentiation was seen to increase on the loosely packed arrays. The results indicate that loosely packed nanotube arrays similar to the ones produced here with a DEG based electrolyte, may provide a favorable template for growth and maintenance of C17.2 neural stem cell line.

I will continue to how our stem cell solutions are used in cool, new discoveries.

Friday, January 30, 2015

Sensitive, Specific and Cost Effective Protein Expression Analysis

Reaching for Cell Based Assay Solutions Excellence

We have been receiving positive feedback from clients using our Quantibody® and RayBio® C-Series Membrane-Based Antibody Arrays. Our manufacturing partner, Raybiotech, is ISO 9000 certified insuring all arrays are made to exacting specification. The cost for measuring a single cytokine runs as low as 16 USD/Cytokine!

We use these arrays to test the blood serum of clients with autoimmune diseases to determine levels of cytokine and growth factor expression vs healthy controls. We also use them to determine proteins secreted by our  USB Derived hMSCs cultured in our hMSC Media. This gives us insight as to the protein expression patterns in our hMSC, Chondrogenesis and Osteogenesis Assays.

Figure: The graph shows cytokine secretion of hMSCs after a continuous 24 day culture. These results were obtained using our select markers from our cytokine and bone metabolism arrays. Data courtesy of Dr. Jim Musick and Tiana Tonrey, Vitro Biopharma.

We are pleased to announce the addition of these new human and mouse arrays:

Quantibody® Human Growth Factor+Neurotrophin+Cytokine Array Q1-10. Precisely measures: Amphiregulin, BDNF, bFGF, BMP-4, BMP-5, BMP-7, beta-NGF, EGF, EGFR, EG-VEGF (PK1), FGF-4,FGF-7 (KGF), GDF-15, GDNF, Growth Hormone, HB-EGF, HGF, IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-6, IGF-1, Insulin, M-CSF R, NGFR (TNFRSF16), NT-3, NT-4, Osteoprotegerin (TNFRSF11B), PDGF-AA, PLGF, SCF, SCF R (CD117/c-kit), TGF alpha, TGF beta 1, TGF beta 3, VEGF-A, VEGFR2, VEGFR3 and VEGF-D.
Mouse C-Series Cytokine Array. C1-2-Semi-quantitavely measures: GCSF,GM-CSF, IL-2, IL-3, IL-4, IL-5, IL-6, IL-6, IL-9, IL-10, IL-12 p40/p70, IL-12 p70, IL-13, IL-17A, IFN-gamma, MCP-1 (CCL2), MCP-5, RANTES (CCL5), SCF, TNF RI (TNFRSF1A), TNF alpha, Thrombopoietin, (TPO) and VEGF-A.

Images: Representative images obtained with RayBio® C-Series Antibody Arrays. These membranes were probed with conditioned media from two different cell lines. Membranes were exposed with Kodak X-Omat® film at room temperature for 1 minute. Note the strong signals of the Positive Control spots in the upper left and lower right corners.

Questions? Do not hesitate to contact me: or direct phone-612-801-1007. Thank you. Pete Shuster, CEO and Owner, Neuromics

Tuesday, January 27, 2015

Human Growth Factor+Neurotrophin+Cytokine Array-Test 40 Markers in on Assay

Sensitive, Specific and Cost Effective

Neuro-immuno and degenerative diseases and disorders commonly show dysregulation of Growth Factors and Cytokines. Using our Quantibody Neuroscience Arrays, we have measured the blood serum of clients with Neuro-inflammatory/immune response diseases/disorders including Autism Spectrum Disorder (ASD). Most showed lowered levels of Growth Factors/Neurotrophins and elevated levels of Inflammatory Response Cytokines.

In order to expand the number of biomarkers measured, we are pleased to announce the addition of our New Growth Factor+Neurotrophin+Cytokine Array. This will enable us to further determine the "finger prints" of these diseases/disorders at the protein level. This array includes: Immunogen: Amphiregulin, BDNF, bFGF, BMP-4, BMP-5, BMP-7, beta-NGF, EGF, EGFR, EG-VEGF (PK1), FGF-4,FGF-7 (KGF), GDF-15, GDNF, Growth Hormone, HB-EGF, HGF, IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-6, IGF-1, Insulin, M-CSF R, NGFR (TNFRSF16), NT-3, NT-4, Osteoprotegerin (TNFRSF11B), PDGF-AA, PLGF, SCF, SCF R (CD117/c-kit), TGF alpha, TGF beta 1, TGF beta 3, VEGF-A, VEGFR2, VEGFR3 and VEGF-D.

I will continue to post testing results here.

Monday, January 19, 2015

Solutions for Studying Neuro-degeneration

Data Rich and Frequently Published

The Neuromics' brand is built, in part, by our proven ability to provide solutions for the study of neuro-degeneration. These include:
A recent example shows the use of one of  MAP-2 markers to study hearing decline with age: Radtke-schuller S, Seeler S and Grothe B(2015) Restricted loss of olivocochlear but not vestibular efferent neurons in the senescent gerbil (Meriones unguiculatus). Front. Aging Neurosci. 7:4. doi:10.3389/fnagi.2015.00004.

Figure: Lipofuscin granules in MSO neurons of an aged gerbil. MSO neurons are MAP2 immunostained (Alexa Fluor 647, red). Lipofuscin granules have been excited with the DAPI excitation wavelengths and appear blue. Confocal images show a maximum projection of image stacks in A and a single optical image of 0.3 µm thickness in the enlargement in B. Scale bar in A: 50 µm and 20 µm in B.

We stand ready to serve you. Should you have interest or questions, do not hesitate to contact me directly: Pete Shuster-Owner/ or direct phone: 612-801-1007. Thank you.

Monday, January 12, 2015

Cancer Associated Fibroblasts (CAFs)-Flow Cytometry and Immunostaining Results

If they Walk and Talk Like CAFs, They Are!

We are experiencing growing demand for are CAFs. They are closely associated with primary tumor cells and participate in the neoplastic process. There is reciprocal communication between CAFs and tumor cells through paracrine effects of secreted growth factors, cytokines & chemokines from both fibroblasts, tumor cells and other tumor-associated cells.

Potential users are asking how well the cells are characterized. The purpose of this posting is to share key gene expression data:
Table: expression of key proteins
Images: Human Lung Adenocarcinoma CAFs stained with Vimentin, aSMA, b-Catenin and DAPI (blue),

Cancer Associated Fibroblasts Gene Expression Data(pdf - 784Kb)-Flow Cytometry and Immunostaining Results.
Questions? Please contact me directly-Pete Shuster- CEO & or 612-801-1007.

Monday, January 05, 2015

Racing into 2015

Thank you for a Great 2014!
EU PCWow. I would like to thank our customers, collaborators and friends for helping us achieve unprecedented success in 2014.

We plan on racing hard into 2015. I would like to highlight our focus areas for the New Year.

Stem Cell Activating Solutions-We have been pilot testing solutions foir balanced immunity and stem cell vitality. Our clients have been mostly peopole with autoimmune related issues. After 6 months of therapy, the improvement in symptoms and test results, for many, has been stunning (see below).
We have developed migration and other assays to test these solutions in vitro using our UCB Derived hMesenchymal Stem Cells. We also use medical testing to prove and improve their therapeutic value. These assays and arrays are available for labs and clinics interested in testing stem cell related solutions. Here're representative data from our Quantibody Array testing program.

Stem and Primary Cell Based Assays-We will continue to add new solutions for your assays. These will include mixed culture that more closely mimic in vivo environments like mixed astroglial-neuron cultures. Below is our hN2TM Human Neurons stained with one of our neuron markers.
Image: hN2 cells grown in culture for 4 days and stained with our chicken polyclonal to Neurofilament light or low molecular weight chain NF-L, a marker of neurons. Many of the differentiating cells show strong cytoplasmic and clearly fibrillar staining for NF-L. Blue stain is DAPI and reveals cell nuclei of some non neuronal cells in this culture.

Check out and join my Stem Cell Clinical Trails Group on Linkedin (4500+members strong).
We wish you a rewarding 2015.

Pete Shuster-
CEO & or 612-801-1007

Wednesday, December 24, 2014

immunoLink Therapies and Treating ASD Children

6-Months of Therapy and Testing Results

I have previously posted our testing and treatment regime for ASD Children. For some of the children, we are seeing marked improvement after 6 months of our treatment regime using solutions aimed at balance immunity and stem cell vitality.

We find that for the children we treat all have varying dysregulated levels of immune/inflammatory response, oxidative stress and growth factor/neurotrophin biomarkers.  We customize treatment plans based on pre-treatment testing results. We then re-test after 6 months to see the level of moderation in these biomarkers/factors. The re-tests are used to show the parents how well these children are responding to treatment and to further adjust plans.

Here I would like to share the results from our more traditional medical testing. These are representative results from one of the Children we are treating.
Graph: ASD Child Pre-treament and 6 month treatment analyte levels vs healthy sweet spots

If you are interested in learning more, please contact me directly (612-801-1007) or Pete Shuster, CEO and Owner of Neuromics and ImmunoLinkTMTherapies.

Thursday, December 18, 2014

immunoLink Therapies-Initial Products

Feeling and performing your best depends on balanced immunity and stem cell vitality

Your current investment in exercise, healthy diet and supplements are aiming you towards what we call the immunoLink sweet spot. If you have hit the bull’s eye, you would be seeking ways to stay there, because this is where you feel awesomely great and are most productive. If you have never been there, now is the time.

Illness, injury and medical procedures push you from the spot, but if you are near or on it, your recovery will be faster and more complete. The far reaches of the immunoLink Spectrum represent a cold wasteland of misery and despair.

How do we Know These Solutions Work?-Our Clients have autoimmune and degenerative diseases or are seeking peak performance. Prior to customizing their treatment strategies, we measure the levels of immune/inflammatory response, oxidative stress, allergens and stem cell health factors in our Clients' blood serum. The levels of these factors are compared with healthy controls. We then re-test after 6 months of treatments. For many the improvement in health and performance are startling. This is confirmed in the re-tests.
Stem-Kine and StemTrophin are central to our treatment strategies. Stem-Kine boosts the levels of circulating blood stem cells. These cells differentiate into immune factors and red blood cells. This boosts oxygen delivery and immunity resulting in greater endurance, mental acuity and cardiovascular health. StemTrophin activates mesenchymal stem cell migration. These cells are essential for immune suppression and then initiating the process of repair and regeneration at the sites of injury or degeneration. To learn more or order by phone, please call me directly at 612-801-1007 or you can also inquire via my e-mail: Pete Shuster, CEO and Owner, Neuromics and immunoLink Therapies.

Monday, December 15, 2014

Stem Cell Based Therapy For Tendinosis

Using Collagen I Producing Cells from Hair Follicles

Learn how these cells can be these cells can be harvested, purified and expanded to treat a chronic, degeneration of tendons.

Saturday, December 06, 2014

Treating Autism-Immune System Balancing and Stem Cell Activating Therapies

Linking the Immune System with Stem Cell Health to Treat ASD Children

We have been testing immune/inflammatory response, oxidative stress and growth factor/neurotrophin biomarkers in the blood sera of Children with Autism Spectrum Disorder (ASD). We did this testing using our Quantibody Arrays.

The purpose of these tests were to establish a baseline for the state of these children's immune system and stem cell health. In this baseline testing, we found that all had high immune/inflammatory response, oxidative stress and low levels of the growth factors/neurotrophins needed for repairing and regenerated damaged cells/tissue (stem cell health).

We then treated these children with customized combinations of immune balancing and stem cell activating agents with the goal of showing that any improvement in ASD related symproms would be confirmed by positive modulations of biomarkers that are dysregulated in this disorder. We re-test at 6 months after initiation of the treatment plans.

The goal of our treatment strategies is to balance the immune system and activate the natural cell/tissue repair and regeneration (stem cell) processes. We call this the immunoLinkTM.

We are seeing improvement in the symptoms of the first 2 children recently retested and a marked improvement in the levels of their biomarkers. Here's data from one of the children. Note that key immune/inflammatory response markers have now moderated to the levels of healthy controls.

Graphs: Comparison of initial testing (red) and 6 month re-test (green) vs healthy controls (blue) for one of our ASD Children

We are developing a website that will have a wealth of information to help parents determine treatment strategies for ASD Children. We are also making our treatment plans and strategies available to interested parents. The website ecosystem will be named immunoLinkTM Therapies.
In the meantime, should you want to investigate if we could help your child, do not hesitate to contact me e-mail: or cell: 612-801-1007. Pete Shuster, CEO and Owner.

Monday, November 24, 2014

Good Axon; Bad Axon: Regeneration in the CNS and Age

"The incapacity of the central nervous pathways to regenerate is a dogma accepted by science..." - Ramon y Cajal

Harvard University has opened access to Michio Wendell Painter's Dissertation: Regeneration in the aging peripheral nervous system. Will Spinal Cord Injury (SCI) and Neurodegenerative Diseases of the PNS become treatable with regenerative therapies? This work provides important insights.

Age plays a central role in regenerative capacities.

Monday, November 17, 2014

Neuropathy Research Solutions

New Publications and Past Postings

Here're are several key postings on Neuropathy and Neuropathic Pain:
Here're some "hot of the press" publications referencing use of Neuron-Glial Markers
Bethany L. Johnson-Kerner, Faizzan S. Ahmad, Alejandro Garcia Diaz, J. Palmer Greene, Steven J. Gray, R. Jude Samulski, Wendy K. Chung, Rudy Van Coster, Paul Maertens, Scott A. Noggle, Christopher E. Henderson and Hynek Wichterle. Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin. Hum. Mol. Genet. (2014) doi: 10.1093/hmg/ddu556. First published online: November 4, 2014.
...MAP2 (1:2,000, Neuromics, CH22103), NF-H (1:2000, Neuromics, CH22104), NF-L (1:200, Neuromics, MO22104)...

Images: Cells grown from adult rat brain. Large cell in middle is stained with mouse monoclonal to NF-L clone DA2 (green). Another type of neuronal lineage cell was stained with rabbit polyclonal to alpha-internexin (red). These cells were mitotic but had several characteristics of neurons. Rat spinal cord homogenate showing the major intermediate filament proteins of the nervous system (lane 1). The remaining lanes show blots of this material stainted with various antibodies including: NF-H, NF-M,, NF-L,, NF66 and GFAP 

Jianfei Guo, Xudong Fu, Xia Cui, Minhua Fan. Contributions of purinergic P2X3 receptors within the midbrain periaqueductal gray to diabetes-induced neuropathic pain. The Journal of Physiological Sciences November 2014.
...An equal volume of total and membrane samples was applied to SDS-PAGE. Membranes were incubated with the rabbit anti-P2X 3 primary antibody (1:1000, Neuromics, Edina, MN, USA) and goat anti-rabbit secondary antibody (1:200, Neuromics, Edina, MN, USA).

Neuropathy Research Solutions Include:

Friday, November 14, 2014

Immune System/Stem Cell Health and Aging

Looking, feeling and  performing your best depends on balanced immunity and stem cell vitality

As we age we encounter:
  • Slower healing
  • Longer recovery time from vigorous exercise
  • More general aches and pains
  • Longer recovery from illness
  • Wrinkled, dry and thinning skin
Why is that? What are the causes? Answers can be found by a better understanding of immune/inflammatory response and stem cell systems. As we age our immune system weakens or becomes dysregulated (autoimmunity) and our stem cell "bank balances" deplete. My friend and world class stem cell therapies expert, Dr. Neil Riordan, gives an excellent description of the process: Your Body’s Stem Cell Bank Account.

To oversimplify, the immune system is responsible for cleansing the body of pathogens, toxins, allergens and damaged tissues/cells. This creates a healthy environment for stem cells to repair and regenerate new, healthy cells and tissue. We call this process the immunoLinkTM.

immunoLink Therapies is a new company of mine slated to launch in the spring of 2015. Our goal is to slow the aging process by offering solutions that balance your immunity and increase your stem cell vitality. Our vanguard product (currently available) is Stem-Kine. It is a blood stem cell booster which increases the level of immune factors and red blood cells in your cardiovascular system. The result is faster healing/recovery and increased endurance via better oxygen delivery.

If you desire to learn more, do not hesitate to call (612-801-1007) or e-mail: Thank you. Pete Shuster

Saturday, November 01, 2014

GFP Labeled Mouse Motor Neurons-Buy Now Save 100 USD

Designed for Motor Neuron Disease Research

I am pleased to add (finally) to our catalog potent, pure and ready to culture motor neurons. I know from the many request I have gotten for these that demand could be out stripping supply.

These are designed foruse in High-throughput fluorescent screening applications. Derived from transgenic mice expressing eGFP using Hb9 motorneuron promoter enables easy tracking and vi sualization of spinal motor neurons without the need for additional fluorescent markers and extended cultures.

Image: GFP+ mMN Mouse Motor Neurons at 2 days post thaw 20X

If you want to learn more about our any of our Neuron-Glial-Astrocyte Based Assay Solutions, do not hesitate to contact me (612-801-1007) or Pete Shuster, Owner and CEO, Neuromics.

Monday, October 27, 2014

100% Serum-Xeno Free Media for Expanding hMSCs

Works as well as our Serum Containing Media

 Selection of Growth and Differentaition media for Mesenechymal Stem Cell Assays is important for the ultimate performance of your cell based assays. The better the media the better the cutures & the lower your costs.

Images: Human mesenchymal stem cells (Catalog no. SC00A1) were plated at 5,000/cm² in a Falcon BD TC-coated T-25 flasks and maintained in serum containing media (Cat. No. SC00B1) and serum-free/xeno-free media (Cat. No. SC00B3) in reduced O2 environment (1% O2, 5% CO2, 90% N2) at 37°C in a humidified chamber. When cells became 80-90% confluent, they were subcultured, counted on a Beckermen Z2 particle counter (range 10-30uM), and passaged. Doubling time of 20-25hrs were calculated in each pass using ln(2*dT)/ln(Cf/Ci), where dT is the time, in hours, from inoculation to detachment; Ci is the initial number of cells plated and Cf is the final number of cells recovered from subculture. There were no apparent differences in doubling time with TC-coated flasks and Laminin/Fibronectin treated flasks.

Testimonial: “We tested the effects of MSCGroTM defined medium using several different lots of human adult primary stem cells and found that MSCGro supports a more robust proliferation rate than normal undefined media. This provided shorter doubling times and increased cellular yield, and maintained the cells in an undifferentiated state. We also found that MSCGro medium is stable under normal laboratory conditions for an extended time period compared to other defined media.” Ben Buehrer, VP and CSO, Zen-Bio

Tuesday, October 21, 2014

Neurite Outgrowth Assays

Cells, Media and Markers

I have previously posted use of our Neurons in Live Content Assays for the study of Neurite Outgrowth: Neurons-Live Content Assays. These assays are critical for the study of repair and regeneration.

A recent publication featured several of our Neuron MarkersSerena Quarta, Bastian E. Baeumer, Nadja Scherbakov1, Manfred Andratsch, Stefan Rose-John, Georg Dechant3, Christine E. Bandtlow, and Michaela Kress: Peripheral Nerve Regeneration and NGF-Dependent Neurite Outgrowth of Adult Sensory Neurons Converge on STAT3 Phosphorylation Downstream of Neuropoietic Cytokine Receptor gp130. The Journal of Neuroscience, 24 September 2014, 34(39): 13222-13233; doi: 10.1523/JNEUROSCI.1209-13.2014.
Live labeling of neuron cultures: After 20 or 48 h, neurons were live-labeled with α-gp130 antibody diluted in cold TNB medium for 30 min on ice. After washing, neurons were incubated with the secondary antibody diluted in cold TNB medium for 30 min and washed with PBS. Cells were fixed either with 4% PFA for 20 min at room temperature (RT) or with methanol at −20°C for 2 min. After permeabilization with 0.01% TX-100 (Pierce) unspecific binding was blocked for 30 min with 10% normal goat serum (Sigma-Aldrich) in PBS. Cells were incubated with the first antibody for 1 h, washed three times for 10 min with PBS and incubated with the appropriate secondary antibody for 30 min, counterstained with 4′, 6-diamidino-2-phenylindole (1:10,000; Sigma-Aldrich) and embedded in Mowiol (Calbiochem). As primary antibodies, α-gp130 (1:50; Neuromics), α-β-III-tubulin clone TuJ-1 (1:1000; R&D Systems), and α-neurofilament-H (α-NF-H; 1:200; Neuromics) were used. Secondary antibodies used were α-goat AlexaFluor 594 (1:1000; Invitrogen), chicken α-mouse AlexaFluor 594 or donkey α-mouse AlexaFluor 488 (1:1000; Invitrogen), and goat α-chicken AlexaFluor 568 (1:10,000; Invitrogen) for fluorescence microcopy.

Images: Reduced density of TuJ-1+ nerve endings in the epidermis in SNS-gp130−/− mice after lesion. A, Representative cross sections of hindpaw glabrous skin of naive and 12 dpl gp130fl/fl and SNS-gp130−/− mice stained with the pan neuronal marker TuJ-1. The dotted line indicates the border between dermis and epidermis. Scale bar, 40 μm. B, Quantification of the total number of TuJ-1+ fibers (NE) per 1000 μm2 of epidermal area shows a significant decrease in density in SNS-gp130−/− mice after lesion compared with control animals (*p < 0.05; n = 4 for each group). Data are presented as mean ± SEM and analyzed by Mann–Whitney U test. C, 3D reconstruction of the deeper layer of the dermis shows fewer nerve bundles in SNS-gp130−/− dermis compared with controls. D, No NF-H+ proprioceptive fibers were detectable in the epidermis of gp130fl/fl animals at 12 dpl. Scale bar, 40 μm.

If you want to learn more about our Neuron-Glial-Astrocyte based assay solutions do not hesitate to contact me (612-801-1007) or Pete Shuster, Owner and CEO, Neuromics.

Sunday, October 05, 2014

The Growing Value of Cancer Associated Fibroblasts or CAFS

Balancing Supply and Demand

There is reciprocal communication between Cancer Associated Fibroblasts (CAFs) and tumor cells. They are now recognized as playing a key role in promoting the malignant process and blocking immune surveillance  They are becoming increasing important in Cancer Drug Discovery Programs.

Their growing value is making it harder for us to source resected tumors. We have been receiving advanced orders from clients who need to insure they have a stock. We have ordered tumors for the below CAFs and will be shipping to those who have place advance orders by the end of November.

NameCatalog #TypeSpeciesApplicationsSizePrice
Human Colorectal Tumor CAFs KitCAF05Human Primary CAFsHCell Assays1,000,000 cells$799
Human Endometrial Adenocarcinoma CAFsCAF01Human Primary CAFsHCell Assays1,000,000 cells$799
Human Ovarian Serous Tumor CAFsCAF02Human Primary CAFsHCell Assays1,000,000 cells$799
Human Lung Adenocarcinoma CAFsCAF07AHuman Primary CAFsHCell Assays1,000,000 cells$799
Human Lung Squamous Cell Tumor CAFsCAF07SCHuman Primary CAFsHCell Assays1,000,000 cells$799
Human Immortalized Pancreatic CAF-Stellate CellsCAF08Human Primary CAFsHCell Assays500,000 Immortized Cells$4,335
Human Pancreatic Tumor Cells KitPXPC3A1Cells+Media KitHCell Assays1,000,000 cells$499
Conditioned Media for Ovarian Serous Tumor CAFSCAF04Cell Growth MediaHCell Assays5 ml$250
Conditioned Media from Endometrial CAFSCAF03Cell Growth MediaHCell Assays5 ml$250
VitroPlus III, low serum, completePC00B1-100Cell Growth MediaHCell Assays100 ml
500 ml
Image: Endometrial CAFs courtesy of Tiana Tonrey, Vitro Biopharma

Should have questions about availability and ship dates for any of these please call (612-801-1007) or e-mail: Thank you.
Pete Shuster, CEO, Neuromics

Tuesday, September 30, 2014

The Dance Between The Immune System and Stem Cells

We named it the  immunoLinkTM 

We have been testing a growing number of Clients with our Quantibody Arrays. Many of of these clients have Autoimmune Disorder Diseases. These range from Rheumatoid Arthritis to Multiple Sclerosis.

These arrays are designed to precisely measure factors or markers (proteins) that are dysregulated by these diseases. We measure the levels of these biomarkers in our Clients' Blood serum. The arrays have also been used to measure the levels of markers in plasma and cell culture supernatants.

Based on results, we are finding links between immune system and stem cell health. We call this the immunoLink. The link shows that when immune/inflammatory response markers are elevated, markers related to stem cell health are depleted.
Here we see the immune/inflammatory response markers IL-6, MCP-1 and TNF-alpha are elevated in our Clients with autoimmunity (A) vs Healthy Controls (HC). We also see lower levels of G-CSF and GM-CSF in these Clients.

G-CSF and GM-CSF are know to play a role in increasing circulating stem cells. GM-CSF is also know to be secreted by Mesenchymal Stem Cells (hMSCs) AND GM-CSF has anti-apoptotic functions on neurons, and is neuroprotective in animal stroke models while G-CSF has a prominent effect on the differentiation of adult neural stem cells (see: BMC Neuroscience 2007, doi:10.1186/1471-2202-8-88).

To us, the immunoLink means achieving a balance between immune system and stem cell health.

We provide immune system balancing and stem cell activating therapies for our Autoimmune Disease Clients and Children with Autism. We first do baseline and follow on testing (each 6 months) to determine how well the therapies are working. Our goal is to bring the many markers we test to healthier levels. As stem cell transplants become more common, moderating levels of immune/inflammatory response in patients could improve outcomes. If you would like to learn more, you can contact me at or 612-801-1007.

Thursday, September 18, 2014

Potent and Pure HUVECs

Only $199 for 500,000 Cells Through Sept. 30

HUVECs (Human Umbilical Vein Endothelial Cells) assays are important for studying the pathology of many diseases and cancers. We provide fresh cells at P1 in T25 flasks. They come to you ready to culture. Initial customer feedback has been favorable regarding ease of culturing and doubling cell populations (up to 16 passages). Now is the time to invest and build your stock of HUVECs!
Image: HUVECs cultured using our Collagel Hydrogel.

Characterization of the cells:
  • Cytoplasmic VWF / Factor VIII: 95% positive by immunofluorescence 
  • Cytoplasmic uptake of Di-I-Ac-LDL: 95% positive by immunofluorescence 
  • Cytoplasmic PECAM1: 95% positive by immunofluorescence 
HUVECs are negative for HIV-1, HBV, HCV, and mycoplasma.

Questions? Contact information: Pete Shuster, CEO and Owner, or direct phone: 612-801-1007.

Wednesday, September 10, 2014

Cytokines and Neuropathic Pain

I have been frequently posting results of testing blood serum of our clients suffering from Autoimmune (including Neuroimmuno) Diseases and Autistic Children. Our testing includes both standard medical testing (serum levels of toxins, metals, pathogen loads and markers like Cortisol, CRP, CDs, ALPS, NSE, S100b). In addition, we also doing testing using our Quantibody® Antibody.

Many of the clients report chronic mild to severe neuropathic pain.

By definition, this pain encompasses a series of heterogeneous conditions with some similar clinical manifestations. Peripheral examples include traumatic nerve injury, diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy or Multiple Sclerosis. (see: Front Pharmacol. 2013; 4: 142.Published online Nov 22, 2013. doi: 10.3389/fphar.2013.00142). It is hard to unravel the cause and effects of this pain,

However, in analyzing the results from our clients' test we notice a relationship between dysregulation of some key cytokines and levels of pain (more data is required to confirm this). Here're our results (n=5)
Figure: Clients reporting pain vs healthy controls.

We will continue posting results here. We are releasing a Custom Quantibody Neuroimmuno-Pain Array which will include more bio-markers suspected to play a role in pain signaling.

Wednesday, August 27, 2014

UCB Derived hMSC-MSCGro™ Media-The Wow Factor!

Neuromics-Vitro Biopharma Cells and Media Used to Treat Cerebral Ischemia

I have frequently posted successful outcomes with our Umbilical Cord Blood Derived Human Mesenchymal Stem Cells and MSCGro Expansion Media. These solutions have been tested head to head with other cell and media options and proven superior in cell behavior, doubling time and total number of passages. Competitive testing, until now, was done in culture.

I am pleased to present a study where our cells and media were selected for the the in vivo treatment of Cerebral Ischemia in Rats. This is a key part of building the foundation for human clinical trials: Chelluboina B, Klopfenstein JD, Pinson DM, Wang DZ, Veeravalli KK. Stem cell treatment after cerebral ischemia regulates the gene expression of apoptotic molecules. Neurochemical research. 39(8): 1511-21 DOI: 10.1007/s11064-014-1341-z
Protocol: Cryo-preserved hUCBSCs obtained from Neuromics/Vitro Biopharma (Golden, CO) were used to establish cultures in MSC-GRO low serum complete MSC medium according to the provided instructions. Cultures were maintained at 37 C in a humidified atmosphere containing 5 % CO2 with a change of culture medium twice a week. When the cell cultures were about 80 % to 90 % confluent, cells were split and subcultured. Cells were detached, washed twice with sterile phosphate buffered saline (PBS), counted and suspended in sterile saline prior to intravenous administration. The cells were intravenously injected (0.25 × 10(6) cells or 1 × 10(6) cells) via the tail vein.

Fig: Stem cell treatment after MCAO procedure reduces caspase-dependent apoptosis and brain damage. a Green fluorescence indicates cleaved caspase 3 protein expression. Representative cleaved caspase3 images were merged with respective DAPI images. Scale bar 100 lm. b Quantification of cleaved caspase-3 protein expression in the ipsilateral hemisphere of untreated [15] and hUCBSCs-treated animals. n C 3. Values are expressed as mean ± SEM; *p\0.05 compared to untreated MCAO subjected animals. c Representative hematoxylin and eosin stained paraffinembedded tissue sections from rat brains. Higher magnification images from the ischemic cortex and striatal regions of MCAOsubjected and untreated animals show interstitial edema and damaged neurons that have a condensed, irregular shaped and darkly stained nuclei which are absent or less frequent in control/hUCBSCs-treated brain sections. Each group consisted of a minimum of three animals. Scale bar value for the magnified images = 100 lm

This provides an in-depth understanding of the molecular mechanisms underlying the neuroprotective effects of mesenchymal stem cells derived from human umbilical cord blood in a rat model of transient focal cerebral ischemia. The study clearly demonstrates the potential of hUCBSCs to regulate various molecules responsible for cell death after transient focal cerebral ischemia followed by reperfusion.

There are some other important factors to consider:

  • Potency and Number of Stem Cells Matter-To move this into clinical applications, Doctors must be allowed to expand Mesenchymal Stem Cells.
  • Media used Matters-it must be best in class and not initiate immune inflammatory response.

We will continue to post studies utilizing Neuromics' Stem Cell Solutions.

Friday, August 22, 2014

We Seek Customer Feedback

Customer Service Matters-A Lot!

We use for customer feedback and input. Yes, it is re-assuring to get the rating and feedback featured in this Video.

We are also interested in hearing when all is not well. If there are issues, we will fix them. We offer all our customers free replacements or full refunds. Testimonials like these matter to us:

"Thank you for working with us in the past year to work out some of our antibody issues (we had run into a bad vial of 2AR ab.) Our work will appear next week online in PNAS- we cite the Neuromics antibodies. Have a great new year!" Dr. Laura Bohn, Associate Professor, OSU

You can contact me directly at any time (direct phone: 612-801-1007) or
I stand ready to serve you. Pete Shuster, CEO and Owner, Neuromics

Monday, August 18, 2014

Stem-Kine and Stem Cell Activation

For Health and Fitness

I have referenced our studies of commercially available Stem Cell Activators or Boosters. Many commercially available supplements make claims of boosting the body's ability increase the production of stem cells.

The catalyst for our researching the active ingredients in these boosters was the desire to find a cost effective way to treat clients with certain autoimmune diseases versus the expensive stem cell transplant options.  We also believed that these supplements could also improve athletic performance.

We have an active internal program to test these in culture using our human stem cell based assays and in actual clients. Stem-Kine is one of the supplements we tested proving it to have therapeutic value. Based on our research and testing, we also believe it is capable of increasing athletic performance by boosting the level of Red Blood Stem Cells.

One way we prove therapeutic value is by testing inflammatory/immune response cytokine, growth factors and oxidative stressors in our client’s blood serum using Quantibody Arrays. We test before prescribing Stem-Kine and other activators. We then re-test every 6 months. As an example,  the graph shows results for TNF-alpha and IL-6 (inflammatory response cytokines)  at initial testing levels (red) and re-tests (green). Here we see clear evidence of these 2 cytokines moderating to healthy levels (lower levels for these are better).

To learn more or order by phone, please call me directly at 612-801-1007 or you can also inquire via my direct e-mail: Pete Shuster, CEO and Owner, CA3 Biosciences, Inc. DBA Neuromics